PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

PBL Assay Science announces a licensing agreement with HumanZyme, Inc. (Chicago, USA) to expand reagent offerings. The agreement allows PBL to provide ~50 authentic human cell-expressed (HCE) cytokines and growth factors directly to scientists worldwide.

HumanZyme, Inc. is a global leader in providing highly authentic recombinant proteins from human cells under the HumanKine® brand and a preferred outsourcing supplier of human protein production. These human cell-expressed proteins mimic native human proteins more closely than proteins from non-human expression systems, such as E. coli, in terms of glycosylation, assembly, location, and structure. 

PBL Assay Science is a major provider of products, assay services, and information related to interferons, cytokines, antibodies, ELISAs, and assay science. The company employs state-of-the-art technology and years of know-how in conducting assay services and manufacturing world-class products for scientists around the globe. Learn more at pblassaysci.com.

"HumanZyme's leadership and innovations in authentic human proteins provide a perfect complement to our unique cytokine and interferon reagents, ELISA, and assay service offerings," said Robert Pestka, CEO, PBL Assay Science. "Introducing these proteins to our product line enhances our ability to help scientists approach their experiments using more biologically relevant research tools."

"For over twenty years, PBL has grown not only in number of products offered but in knowledge around interferons, cytokines and assay science," said Sean Doctor, Executive Vice President and GM, HumanZyme, Inc. "Combining our human cell-expressed reagents with PBL's expertise expands both companies' capability to address researchers' most difficult problems."

The agreement between PBL Assay Science and HumanZyme, Inc. begins this month. Human cell-expressed (HCE) proteins in the agreement include members of the human TGF beta, Fibroblast Growth Factor (FGF), Hematopoietin and Interleukin, and Tyrosine Kinase Receptor Signaling families, and TNF-alpha.               

Source:

PBL Assay Science

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PBL Assay Science. (2019, June 19). PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings. News-Medical. Retrieved on October 27, 2021 from https://www.news-medical.net/news/20140220/PBL-Assay-Science-HumanZyme-ink-licensing-agreement-to-expand-reagent-offerings.aspx.

  • MLA

    PBL Assay Science. "PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings". News-Medical. 27 October 2021. <https://www.news-medical.net/news/20140220/PBL-Assay-Science-HumanZyme-ink-licensing-agreement-to-expand-reagent-offerings.aspx>.

  • Chicago

    PBL Assay Science. "PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings". News-Medical. https://www.news-medical.net/news/20140220/PBL-Assay-Science-HumanZyme-ink-licensing-agreement-to-expand-reagent-offerings.aspx. (accessed October 27, 2021).

  • Harvard

    PBL Assay Science. 2019. PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings. News-Medical, viewed 27 October 2021, https://www.news-medical.net/news/20140220/PBL-Assay-Science-HumanZyme-ink-licensing-agreement-to-expand-reagent-offerings.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.